ライフサイエンスコーパス: DOTATOC

1 r and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET wi

2 68Ga-DOTATOC is an excellent specific ligand for this hSSTr2

3 68Ga-DOTATOC PET/CT detected additional hepatic and/or extrah

4 d in the protocol of comparison between 68Ga-DOTATOC PET/CT and CT and/or MRI.

5 omatostatin receptor subtype 2 (hSSTr2)-68Ga-DOTATOC reporter system has several attractive features

6 More important, 68Ga-DOTATOC PET/CT impacted our treatment decision in more t

7 s, a rapid internalized accumulation of 68Ga-DOTATOC in the SSTr2-expressing cells, and a rapid excre

8 Small-animal PET of 68Ga-DOTATOC in tumor-bearing mice demonstrated that the in v

9 The in vivo uptake of 68Ga-DOTATOC, at 2 h after injection, was low in all organs e

10 Overall, 68Ga-DOTATOC PET/CT altered our treatment decision based on C

11 In all 52 patients, 68Ga-DOTATOC PET/CT demonstrated pathologically increased upt

12 tients with unknown primary tumor site, 68Ga-DOTATOC PET/CT visualized the primary tumor region (jeju

13 In this study, 68Ga-DOTATOC PET/CT proved clearly superior to CT and/or MRI

14 d elsewhere and consecutively underwent 68Ga-DOTATOC PET/CT in our institution.

15 tumor-bearing mice were evaluated with 68Ga-DOTATOC PET studies.

16 GEP-NET-patients received whole-body [68Ga]-DOTATOC-PET/CT, BIA, and DXA-scans.

17 In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed

18 s mellitus risk was higher before than after DOTATOC (estimate, 0.0032; P < 0.001), and overall survi

19 cted the somatostatin receptor imaging agent DOTATOC as the foundation for developing a dual-labeled

20 using the DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET.

21 , radiolabeled somatostatin analogs, such as DOTATOC, have been introduced for PET imaging of meningi

22 Because DOTATOC has undergone extensive clinical testing, this h

23 Cobalt-labeled DOTATATE, DOTATOC, and DOTANOC were prepared with (57)Co or (58m)C

24 tients receiving RLT with (177)Lu-DOTATATE, -DOTATOC, or -prostate-specific membrane antigen and show

25 after the administration of (177)Lu-DOTATATE/DOTATOC provides a 3-dimensional dose map and can be use

26 d benefit of treatment with (177)Lu-DOTATATE/DOTATOC.

27 underwent WB-DWI MRI and gallium 68 ((68)Ga)-DOTATOC PET/CT before and 7 weeks after one PRRT cycle.

28 P values of 0.004 and 0.008) than for (68)Ga-DOTATOC (1.9, with an interquartile range of 1.4-2.9).

29 ngle 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of peptide) and 2 single 150-MBq intrave

30 compared with the reference compound, (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

31 high-yield preparation of injectable (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) t

32 , respectively, and 59% for 15 mug of (68)Ga-DOTATOC (P < 0.001).

33 nistered a mean of 6.0 +/- 0.5 MBq of (68)Ga-DOTATOC (RM1-SSTR allograft), 5.3 +/- 0.3 MBq of (68)Ga-

34 as to compare the respective value of (68)Ga-DOTATOC and (18)F-DOPA PET/CT for initial staging or pre

35 For detection of distant metastases, (68)Ga-DOTATOC and (18)F-DOPA PET/CT performed equally well on

36 (68)Ga-DOTATOC and (18)F-DOPA PET/CT were concordantly positive

37 ted SiNET patients who underwent both (68)Ga-DOTATOC and (18)F-DOPA PET/CT within a 6-mo interval wit

38 on-based analysis was 91% and 98% for (68)Ga-DOTATOC and (18)F-DOPA PET/CT, respectively (P = 0.18).

39 s had known metastases, documented by (68)Ga-DOTATOC and (18)F-DOPA PET/CT.

40 dy period, 21 patients underwent both (68)Ga-DOTATOC and (18)F-DOPA PET/CT.

41 compare the uptake of the PET tracers (68)Ga-DOTATOC and (64)Cu-DOTATATE in large arteries, in the as

42 neuroendocrine tumors underwent both (68)Ga-DOTATOC and (64)Cu-DOTATATE PET/CT scans, in random orde

43 ncologic patients, vascular uptake of (68)Ga-DOTATOC and (64)Cu-DOTATATE was found, with highest upta

44 pared with whole-body images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

45 n the 2 patients with MTC imaged with (68)Ga-DOTATOC and (68)Ga-DOTA-MGS5, the same total number of l

46 (68)Ga-DOTATOC and (68)Ga-DOTATATE are 2 radiolabeled somatosta

47 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostati

48 (68)Ga-DOTATOC and (68)Ga-DOTATATE are suited equally well for

49 tumor volume, or SSTR volume between (68)Ga-DOTATOC and (68)Ga-DOTATATE at any time point.

50 litatively compare the performance of (68)Ga-DOTATOC and (68)Ga-DOTATATE in the context of subsequent

51 body PET/CT at 1 h after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

52 body PET/CT at 1 h after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

53 ol for semiquantitative assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake and as a therap

54 ic for semiquantitative assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake.

55 rson correlation of 0.98 and 0.93 for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

56 ope, 0.81) and 0.97 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

57 ope, 0.71) and 0.92 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

58 ges than in the whole-body images for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

59 ope, 0.81) and 0.97 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

60 The radiochemical purity of both (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC determined by high-perfo

61 (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC investigational radiopha

62 objective was to assess the value of (68)Ga-DOTATOC and carbidopa-assisted (18)F-fluorodihydroxyphen

63 patients also received intraarterial (68)Ga-DOTATOC and underwent PET/CT.

64 Imaging with (68)Ga-DOTATOC appears promising especially in poorly different

65 d PET imaging with (68)Ga-DOTATATE or (68)Ga-DOTATOC as a prerequisite for the administration of pept

66 liver ratio was marginally higher for (68)Ga-DOTATOC at the 3-h time point (P = 0.037).

67 taanalysis summarizes the efficacy of (68)Ga-DOTATOC for several distinct indications and is intended

68 ons were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respectively.

69 at ultimately resulted in approval of (68)Ga-DOTATOC in August 2019.

70 d in increased radioligand binding of (68)Ga-DOTATOC in NET cells.

71 mance of (64)Cu-DOTATATE with that of (68)Ga-DOTATOC in NET patients.

72 n:(64)Cu-DOTATATE has advantages over (68)Ga-DOTATOC in the detection of lesions in NET patients.

73 OTATATE was significantly higher than (68)Ga-DOTATOC in the vascular regions both when calculated as

74 was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significantly more lesions were

75 administration of (68)Ga-DOTATATE and (68)Ga-DOTATOC is 2.1 mSv for both tracers.

76 Conclusion:(68)Ga-DOTATOC is useful for evaluating the presence and extent

77 illed experiences associated with the (68)Ga-DOTATOC NDA process.

78 tment, the NET patients injected with (68)Ga-DOTATOC or (123)I MIBG emitted an average EDR-1m roughly

79 often slightly greater than those for (68)Ga-DOTATOC or (68)Ga-DOTANOC but less than those for (111)I

80 ynamic PET/CT scan after injection of (68)Ga-DOTATOC or (68)Ga-DOTATATE.

81 Methods: All patients who underwent (68)Ga-DOTATOC or carbidopa-assisted (18)F-DOPA PET/CT for susp

82 Interim (68)Ga-DOTATOC PET does not provide information for treatment p

83 rom healthy tissues were estimated on (68)Ga-DOTATOC PET scans of 11 meningioma patients and 12 HGG p

84 y of pretherapeutic and early interim (68)Ga-DOTATOC PET tumor uptake and volumetric parameters and a

85 tide was assessed quantitatively with (68)Ga-DOTATOC PET, with the finding that increased occupancy r

86 All patients underwent a (68)Ga-DOTATOC PET/computed tomography (CT) at baseline and sev

87 (68)Ga-DOTATOC PET/CT (CT without contrast, low-dose) was perfo

88 rmed by (18)F-FDG PET/CT (LC and MM), (68)Ga-DOTATOC PET/CT (GEP NET), and (68)Ga-labeled prostate-sp

89 Results: (68)Ga-DOTATOC PET/CT and (18)F-DOPA PET/CT individually identi

90 scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a head-to-head basis.

91 scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a head-to-head basis.

92 All patients underwent (68)Ga-DOTATOC PET/CT at baseline and 7 wk after the first PRRT

93 s, SRETVwb and TLSREwb extracted from (68)Ga-DOTATOC PET/CT could predict TTP or overall survival and

94 pre- and posttreatment imaging using (68)Ga-DOTATOC PET/CT from patients treated with PRRT at the Un

95 Visual assessment of (68)Ga-DOTATOC PET/CT images used a 4-point scale for classific

96 ET and unknown primary site underwent (68)Ga-DOTATOC PET/CT in a single-site prospective study.

97 This study evaluated the impact of (68)Ga-DOTATOC PET/CT in detecting recurrence or metastases in

98 somatostatin receptor tumor burden on (68)Ga-DOTATOC PET/CT in patients with well-differentiated (WD)

99 OPA PET/CT detected more lesions than (68)Ga-DOTATOC PET/CT in the studied patients.

100 Conclusion:(68)Ga-DOTATOC PET/CT is an effective modality in the localizat

101 usively by (18)F-DOPA PET/CT and 3 by (68)Ga-DOTATOC PET/CT only.

102 s showed intense uptake at diagnostic (68)Ga-DOTATOC PET/CT or in an (111)In-octreotide scan.

103 teria in Solid Tumors version 1.1 and (68)Ga-DOTATOC PET/CT quantitative responses to predict overall

104 hods: We retrospectively analyzed the (68)Ga-DOTATOC PET/CT scans of 84 patients with histologically

105 detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions w

106 detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions w

107 ons as assessed by CoVs obtained from (68)Ga-DOTATOC PET/CT scans.

108 (68)Ga-DOTATOC PET/CT should be considered in the case of negat

109 ministered activity was 122 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (18)F-FDOPA PET/CT

110 A scan was classified unconfirmed if (68)Ga-DOTATOC PET/CT suggested a primary, however, no histolog

111 The (68)Ga-DOTATOC PET/CT was considered true-positive if the posit

112 The rate of positive (68)Ga-DOTATOC PET/CT was significantly higher in poorly differ

113 (68)Ga-DOTATOC PET/CT was true-positive in 5 patients (10 tumor

114 lesions displaying positive uptake on (68)Ga-DOTATOC PET/CT was visualized with (68)Ga-DOTA-MGS5 (an

115 (18)F-DOPA and (68)Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning

116 (18)F-DOPA and (68)Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 1

117 e values for (68)Ga-OPS202 PET/CT and (68)Ga-DOTATOC PET/CT were similar ( approximately 98%).

118 n neuroendocrine tumors who underwent (68)Ga-DOTATOC PET/CT were studied.

119 n patients with tumor localization on (68)Ga-DOTATOC PET/CT, but differences were not significant.

120 tients with true-positive findings on (68)Ga-DOTATOC PET/CT, CT alone but not ultrasound identified 2

121 5) and nodal lesions (P = 0.003) than (68)Ga-DOTATOC PET/CT, including nodes at the origin of mesente

122 nt both intravenous and intraarterial (68)Ga-DOTATOC PET/CT, tumor SUV(max) was compared between intr

123 (68)Ga-DOTATOC PET/MRI combines the advantages of PET in the ac

124 the (68)Ga-OPS202 scans than for the (68)Ga-DOTATOC scan: the median of the mean tumor-to-background

125 (68)Ga-DOTATOC showed 26 lesions not found on (64)Cu-DOTATATE,

126 and increased radioligand binding of (68)Ga-DOTATOC to these tumor cells.

127 clusion: Normal baseline IBI and high (68)Ga-DOTATOC tumor uptake predict better outcome in NET patie

128 eceptor type 2 (SSTR2) expression and (68)Ga-DOTATOC uptake by human NET cell lines were investigated

129 (68)Ga-DOTATOC uptake was higher in mediastinal blood pool at t

130 PCA correlated with(18)F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptake, respectively, an

131 Although (68)Ga-DOTATOC would seem to be useful in evaluating patients w

132 interim (68)Ga-DOTA-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography (PET) tumor uptake

133 As compared with (68)Ga-DOTATOC, (18)F-DOPA PET/CT detected more hepatic (P < 0.

134 ith novel somatostatin analogs (e.g., (68)Ga-DOTATOC, (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOT

135 (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octr

136 undergoing PET/CT with (18)F-FDOPA or (68)Ga-DOTATOC, a somatostatin analog.

137 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has be

138 scribes the start-to-finish story for (68)Ga-DOTATOC, including a description of the clinical trials,

139 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly because of higher uptake in liver and ki

140 TATATE showed 42 lesions not found on (68)Ga-DOTATOC, of which 33 were found to be true-positive on f

141 Uptake of (64)Cu-DOTATATE, but not of (68)Ga-DOTATOC, was correlated with cardiovascular risk factors

142 For each PET/CT scan, all (68)Ga-DOTATOC-avid lesions were independently segmented by 2 o

143 (68)Ga-DOTATOC-avid tumor lesions were semi-automatically delin

144 (68)Ga-DOTATOC-avid tumor lesions were semiautomatically deline

145 tio [HR], 0.45; P = 0.024), whereas a (68)Ga-DOTATOC-avid tumor volume higher than 578 cm(3) (75th pe

146 atio (HR) 0.45; P = 0.024), whereas a (68)Ga-DOTATOC-avid tumor volume higher than 578 ml (P75) was a

147 In addition, a (68)Ga-DOTATOC-based molecular-imaging method provides a tool f

148 ibility of a dynamic whole-body (DWB) (68)Ga-DOTATOC-PET/CT acquisition in patients with well-differe

149 irst showing the feasibility of a DWB (68)Ga-DOTATOC-PET/CT acquisition in WD-NETs.

150 ixty-one patients who underwent a DWB (68)Ga-DOTATOC-PET/CT for a histologically proven/highly suspec

151 0 tumor lesions, but in both patients (68)Ga-DOTATOC-PET/CT revealed further tumor lesions not detect

152 (68)Ga-DOTATOC-PET/MRI ((68)Gallium-DOTATOC-positron emission t

153 lesion was found corresponding to the (68)Ga-DOTATOC-positive site.

154 ent baseline PET/CT using intravenous (68)Ga-DOTATOC.

155 whereas no association was found with (68)Ga-DOTATOC.

156 pancy level using the PET radiotracer (68)Ga-DOTATOC.

157 mparable to those with (18)F-DOPA and (68)Ga-DOTATOC.

158 pared with 45 lesions visualized with (68)Ga-DOTATOC.

159 (177)Lu-DOTATATE and (68)Ga-DOTATOC/(68)Ga-DOTATATE are used, respectively, for PRRT

160 (18)F-FDG and somatostatin receptor ((68)Ga-DOTATOC/DOTATATE) PET to indicate a metabolic shift and

161 itivity with the antagonist than with (68)Ga-DOTATOC: 94% and 88% for 50 and 15 mug of (68)Ga-OPS202,

162 [(68)Ga]Ga-DOTATOC uptake in 508 [(68)Ga]Ga-DOTATOC PET scans from 178 patients, performed for confi

163 at could differentiate myocardial [(68)Ga]Ga-DOTATOC uptake in 31 patients with MRI-ascertained AM (A

164 with the detection of myocardial [(68)Ga]Ga-DOTATOC uptake in 508 [(68)Ga]Ga-DOTATOC PET scans from

165 Here, we report our experience with [(68)Ga]-DOTATOC PET/MRI.

166 (68)Ga-DOTATOC-PET/MRI ((68)Gallium-DOTATOC-positron emission tomography/magnetic resonance

167 men magnetic resonance imaging and gallium68-DOTATOC positron emission tomography scan demonstrated t

168 irst candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radi

169 Recently, (57)Co-labeled DOTATOC, an octreotide analog, was shown to have the hig

170 nction with the production of (68)Ga-labeled DOTATOC and Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-HBED-CC)

171 range [IQR], 132-228) compared with (177)Lu-DOTATOC (126 d; IQR, 118-129).

172 tion of (177)Lu-DOTATATE (n = 22) or (177)Lu-DOTATOC (n = 7).

173 F counts, the difference observed in (177)Lu-DOTATOC and (177)Lu-PSMA treatment groups was unexplaine

174 We evaluated PRRT with SSTR agonist (177)Lu-DOTATOC and antagonist (177)Lu-DOTA-JR11 longitudinally

175 (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unr

176 s and compared with the SSTR agonist (177)Lu-DOTATOC in 247 patients undergoing PRRT on the same dosi

177 eatic neuroendocrine tumors received (177)Lu-DOTATOC in 33 treatment cycles.

178 177)Lu-DOTA-LM3 than for the agonist (177)Lu-DOTATOC in the whole body and in the kidneys, spleen, an

179 s RIFs side by side in recipients of (177)Lu-DOTATOC or (177)Lu-prostate specific membrane antigen-61

180 ignificantly more RIFs were found in (177)Lu-DOTATOC recipients by comparison, despite lower dose rat

181 tly higher for (177)Lu-PSMA than for (177)Lu-DOTATOC treatment at every time point.

182 were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity oc

183 reclinically, it was shown to reduce (177)Lu-DOTATOC uptake in the kidneys while improving bioavailab

184 econd therapy cycle, tumor uptake of (177)Lu-DOTATOC was significantly lower (P = 0.01) whereas (177)

185 Results: Compared with (177)Lu-DOTATOC, (177)Lu-DOTA-JR11 treatment resulted in an incr

186 (177)Lu-labeled radioligand therapy ((177)Lu-DOTATOC, 26; (177)Lu-PSMA, 22) to quantify blood lymphoc

187 ions of 100 muL of saline, 30 MBq of (177)Lu-DOTATOC, or 20 MBq of (177)Lu-DOTA-JR11 with an interval

188 tions of 100 uL of saline, 30 MBq of (177)Lu-DOTATOC, or 20 MBq of (177)Lu-DOTA-JR11 with an interval

189 DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octre

190 Compared with RIF counts of (177)Lu-DOTATOC, those of (177)Lu-PSMA were significantly higher

191 pronounced cytotoxic effect than did (177)Lu-DOTATOC.

192 produce (161)Tb-DOTATOC, as used for (177)Lu-DOTATOC.

193 pronounced cytotoxic effect than did (177)Lu-DOTATOC.

194 eptide therapy with (90)Y-DOTATOC or (177)Lu-DOTATOC.

195 3 and 83 h (range, 30-122 h) for [(177)Lu]Lu-DOTATOC (P = 0.012).

196 therapeutic index compared with [(177)Lu]Lu-DOTATOC after injection of 1.4-2.1 times lower activitie

197 d 2.7 Gy (range, 1.3-5.3 Gy) for [(177)Lu]Lu-DOTATOC and 0.29 Gy (range, 0.16-0.39 Gy) and 3.3 Gy (ra

198 3.4 Gy (range, 0.8-10.2 Gy) for [(177)Lu]Lu-DOTATOC and 11.5 Gy (range, 4.7-22.7 Gy) for [(177)Lu]Lu

199 In total, 1 [(177)Lu]Lu-DOTATOC and 2-3 [(177)Lu]Lu-DOTA-JR11 treatment cycles w

200 a total of 106 [(90)Y]Y-DOTATOC/[(177)Lu]Lu-DOTATOC cycles were included.

201 ndard injected radioactivity) of [(177)Lu]Lu-DOTATOC followed by 3.3-4.9 GBq (2 GBq/m(2) x body surfa

202 er injection of [(90)Y]Y-DOTATOC/[(177)Lu]Lu-DOTATOC in 19% of patients.

203 tion of [(161)Tb]Tb-DOTA-LM3 and [(177)Lu]Lu-DOTATOC in the same cohort of patients with grade 1 and

204 ed somatostatin receptor agonist [(177)Lu]Lu-DOTATOC in the same patients with progressive, standard

205 2 cycles of [(90)Y]Y-DOTATOC or [(177)Lu]Lu-DOTATOC therapy from early 2000 to early 2022.

206 oses of [(161)Tb]Tb-DOTA-LM3 and [(177)Lu]Lu-DOTATOC were 36.6 Gy/GBq (range, 15-196 Gy/GBq) and 7.0

207 diopharmaceuticals (0.9-2.5 kDa)-[(177)Lu]Lu-DOTATOC, [(177)Lu]Lu-DOTATATE, [(177)Lu]Lu-DOTA-JR11, [(

208 The renal uptake of [(177)Lu]Lu-DOTATOC, [(177)Lu]Lu-DOTATATE, and [(177)Lu]Lu-DOTA-JR11

209 Bq (range, 0.03-0.06 Gy/GBq) for [(177)Lu]Lu-DOTATOC, respectively (both P = 0.008).

210 (161)Tb]Tb-DOTA-LM3 and 1 GBq of [(177)Lu]Lu-DOTATOC, with a 4-wk interval between injections.

211 e 2 lymphopenia after 1 cycle of [(177)Lu]Lu-DOTATOC.

212 tumor absorbed dose than that of [(177)Lu]Lu-DOTATOC.

213 for [(161)Tb]Tb-DOTA-LM3 as for [(177)Lu]Lu-DOTATOC.

214 ting yttrium 90-DOTA Phe1-Tyr(3)-octreotide (DOTATOC) treatment for mNET (EudraCT no.

215 MIBG) and (90)Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic agents for t

216 the radiolabeling efficiency and efficacy of DOTATOC, providing yields of greater than 99% (decay-cor

217 Results: The radiolabeling of DOTATOC with (161)Tb was readily achieved with a high ra

218 , where it was used for the radiolabeling of DOTATOC.

219 (111)In-octreotide (2 papers, sensitivity of DOTATOC on a per-lesion basis was 100%, for (111)In-octr

220 tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in hea

221 Uptake of DOTATOC on NETs maximized at about 24 h after injection.

222 cal extracranial tumor showed high uptake of DOTATOC.

223 )Y-labeled somatostatin analogs (DOTATATE or DOTATOC).

224 fore, like (177)Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatm

225 post-processed (68)Ga was used to radiolabel DOTATOC in combination with high-purity water and variou

226 processed eluate has been used to radiolabel DOTATOC in yields of approximately 97% +/- 0.25% at 80 d

227 ed time-dependent biodistribution of (161)Tb-DOTATOC in the liver, kidneys, spleen, and urinary bladd

228 tion of relatively low activities of (161)Tb-DOTATOC using y-scintigraphy and SPECT/CT.

229 The application of (161)Tb-DOTATOC was well tolerated, and no related adverse event

230 parate studies, 596 and 1,300 MBq of (161)Tb-DOTATOC were administered to a 35-y-old male patient wit

231 the synthesis and quality control of (161)Tb-DOTATOC with a fully automated process conforming to goo

232 ed production and quality control of (161)Tb-DOTATOC with clinically applicable specifications and ac

233 cassette-module synthesis to produce (161)Tb-DOTATOC, as used for (177)Lu-DOTATOC.

234 erse events after the application of (161)Tb-DOTATOC.

235 ologic and tumor biodistributions of (161)Tb-DOTATOC.

236 s and safe preparation of injectable (161)Tb-DOTATOC.

237 r standard therapies were treated with (90)Y-DOTATOC (dosage of 1.1 or 5.5 GBq) or with (177)Lu-DOTAT

238 57, using 92% of the maximum tolerated (90)Y-DOTATOC activity supplemented with 76% of the maximum to

239 etric organ values for (131)I-MIBG and (90)Y-DOTATOC along with critical organ-dose limits.

240 design and suggest the safety of using (90)Y-DOTATOC and (131)I-MIBG.

241 st commonly used radiopharmaceuticals, (90)Y-DOTATOC and (177)Lu-DOTATATE.

242 (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for trea

243 esectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or p

244 tes mellitus, including 47 cases after (90)Y-DOTATOC and 25 cases after combined treatment.

245 ET patients received up to 4 cycles of (90)Y-DOTATOC at 1.85 GBq/m(2)/cycle with a maximal kidney bio

246 g is 3 cycles of 1.85 GBq/m(2)/dose of (90)Y-DOTATOC coadministered with amino acids.

247 n addition, the single treatment using (90)Y-DOTATOC did not induce tumor shrinkage, indicating that

248 Combining (131)I-MIBG and (90)Y-DOTATOC for radiotherapy of neuroendocrine tumors can si

249 y applied doses were 7,400 MBq/m(2) of (90)Y-DOTATOC in 2 fractions.

250 paper reports a study of the uptake of (90)Y-DOTATOC in meningiomas and high-grade gliomas (HGGs) and

251 Uptake of (90)Y-DOTATOC in meningiomas was high in all studied patients.

252 rine tumor (NET) patients treated with (90)Y-DOTATOC in the setting of a prospective phase II trial.

253 rine tumor (NET) patients treated with (90)Y-DOTATOC in the setting of a prospective phase II trial.

254 ide receptor radionuclide therapy with (90)Y-DOTATOC is safe in children and young adults and demonst

255 tor-targeted radionuclide therapy with (90)Y-DOTATOC may be a therapeutic option.

256 somatostatin radiopeptide therapy with (90)Y-DOTATOC or (177)Lu-DOTATOC.

257 epatic intraarterial administration of (90)Y-DOTATOC peptide receptor radionuclide therapy (PRRT) wou

258 ndocrine tumors using a combination of (90)Y-DOTATOC plus (131)I-MIBG.

259 sing combination therapy as opposed to (90)Y-DOTATOC PRRT alone.

260 (90)Y-DOTATOC therapy is feasible and may represent a promisin

261 tudy was to conduct a phase I trial of (90)Y-DOTATOC to determine the dose-toxicity profile in childr

262 fore and at 2 months after intravenous (90)Y-DOTATOC treatment.

263 f the tumor-dose ratio, defined as the (90)Y-DOTATOC tumor dose per megabecquerel divided by the (131

264 3.5 +/- 0.2 GBq (94.7 +/- 5.4 mCi) of (90)Y-DOTATOC were administered into the proper hepatic artery

265 Then, 3.5 0.2 GBq (94.7 5.4 mCi) of (90)Y-DOTATOC were administered into the proper hepatic artery

266 patients treated, 5 patients received (90)Y-DOTATOC with a cumulative activity of 11.1 GBq and 37 pa

267 up to four cycles of 1.85 GBq/m2/cycle (90)Y-DOTATOC with a maximal kidney biologic effective dose of

268 etermine the highest tolerable dose of (90)Y-DOTATOC, with administered activities of 1.11, 1.48, and

269 isk profile were treated with systemic (90)Y-DOTATOC.

270 with respect to either (131)I-MIBG or (90)Y-DOTATOC.

271 r outcome in NET patients treated with (90)Y-DOTATOC.

272 e, 2-24 y) received at least 1 dose of (90)Y-DOTATOC; diagnoses included neuroblastoma, embryonal and

273 insulinoma and at least 2 cycles of [(90)Y]Y-DOTATOC or [(177)Lu]Lu-DOTATOC therapy from early 2000 t

274 of 32 patients with a total of 106 [(90)Y]Y-DOTATOC/[(177)Lu]Lu-DOTATOC cycles were included.

275 ypoglycemia just after injection of [(90)Y]Y-DOTATOC/[(177)Lu]Lu-DOTATOC in 19% of patients.